Related Experiment Video
Updated: Jan 16, 2026

07:32
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.9K
Bulk and Single-Cell Transcriptomes Reveal Exhausted Signature in Prognosis of Hepatocellular Carcinoma
Ruixin Chun1, Haisen Ni1, Ziyi Zhao1
1College of Computer and Control Engineering, Northeast Forestry University, Harbin 150040, China.
Genes
|September 27, 2025
Summary
T cell exhaustion (TEX) in hepatocellular carcinoma (HCC) impacts prognosis and immunotherapy response. This study identified a 26-gene signature linked to TEX, offering potential for personalized HCC treatment strategies.
Area of Science:
- Immunology
- Oncology
- Genomics
Background:
- Hepatocellular carcinoma (HCC) is a heterogeneous cancer with poor outcomes.
- T cell exhaustion (TEX) contributes to immune evasion and treatment resistance in HCC.
- Understanding TEX is crucial for improving HCC patient prognosis.
Purpose of the Study:
- To characterize TEX-related transcriptional features in HCC.
- To integrate single-cell and bulk RNA sequencing data for comprehensive analysis.
- To identify a prognostic gene signature associated with TEX in HCC.
Main Methods:
- Calculated TEX scores using a 65-gene signature to classify samples into high-TEX and low-TEX groups.
- Identified differentially expressed genes from both scRNA-seq and bulk RNA-seq data.
- Developed a 26-gene prognostic signature using univariate Cox and LASSO regression.
Main Results:
- High-TEX group showed increased immune checkpoint and antigen presentation molecules.
- This suggests a more immunosuppressive yet potentially immunotherapy-responsive tumor microenvironment.
- Functional enrichment and PPI network analysis confirmed gene roles in immune regulation and tumor progression.
Conclusions:
- Provided a comprehensive characterization of the TEX landscape in HCC.
- Identified a robust 26-gene signature associated with prognosis and immune infiltration.
- Highlighted the potential of targeting TEX for personalized HCC immunotherapies.

